ABSTRACT Pseudomonas aeruginosa infections are challenging due to intrinsic and acquired resistance mechanisms. We report here the draft genome sequences of two multidrug-resistant strains-PAL0.1, isolated from the airways of an intensive care unit (ICU) patient with ventilator-associated pneumonia, and PAL1.1, isolated from blood cultures of an ICU patient with sepsis.
P
seudomonas aeruginosa is one of the most common nosocomial pathogens, responsible for acute infections such as ventilator-associated pneumonia and infections in immunocompromised hosts, such as burn patients. Due to increasing multidrug resistance (MDR), P. aeruginosa is among the top-priority pathogens according to the World Health Organization (1) . In addition to intrinsic and acquired antibiotic resistance mechanisms (decreased outer membrane permeability, enzymatic antibiotic deactivation, and efflux pumps), P. aeruginosa forms biofilms that decrease exposure to antimicrobials. Treating MDR P. aeruginosa infections is increasingly challenging and requires new therapeutic approaches. Two representative MDR clinical strains related to the well-described PAO1 and PA14 phylogenetic clades were isolated from patients in the Lille University Teaching Hospital (CHU Lille, France)-PAL1.1, isolated from the airways of an intensive care unit (ICU) patient with ventilator-associated pneumonia, and PAL0.1, isolated from blood cultures of an ICU patient with sepsis. Both strains were isolated from blood cultures using the Virtuo automated system (bioMérieux, Marcyl'Étoile, France) and were identified by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Inc., Billerica, MA). The complete genome sequences of these strains were determined in order to assess lectin-specific bacterial adhesion inhibiting glycosylated calixarenes against multidrugresistant (MDR) Pseudomonas aeruginosa strains.
Genomic DNA from P. aeruginosa strains PAL0.1 and PAL1.1 was extracted after an overnight culture using a QIAamp DNA minikit (Qiagen, Hilden, Germany). Libraries were prepared using the Nextera XT DNA Library prep kit (Illumina, San Diego, CA), followed by paired-end (2 ϫ 150-bp) sequencing on an Illumina HiSeq platform. Genome coverage was about 650ϫ for each isolate. Paired reads were filtered, and Nextera adapters were removed using Trimmomatic (2). Processed reads were de novo assembled with the Unicycler pipeline on a Galaxy server version 0.4.1.1 using default settings (3). Annotation was performed using the NCBI Prokaryotic Genome Annotation Pipeline version 4. (3=)-llb, ant(2Љ)-la, and aadA11] , 2 beta-lactam resistance genes (blaOXA-50 and blaPAO), the fosfomycin resistance gene fosA, the sulfonamide resistance gene sul1, the phenicol resistance gene catB7, and the trimethoprim resistance gene dfrB1.
Multilocus sequence typing (MLST) was performed using MLST version 2.0 from the Center for Genomic Epidemiology (5). PAL0.1 (PAO1 clade) is a Verona integrinencoded metallo-beta-lactamase (VIM-2)-producing strain that belongs to the sequence type 111 (ST-111), a clonal strain responsible for nosocomial infection epidemics worldwide (6, 7). PAL1.1 (PA14 clade) shares an acquired resistance genotype commonly observed worldwide among clinical P. aeruginosa strains (8) belonging to ST-2613.
Data availability. The whole-genome shotgun project of PAL0.1 and PAL1.1 has been deposited in DDBJ/EMBL/GenBank under the accession no. QFRL00000000 and QFRM00000000, respectively. The SRA accession no. is SRP155966.
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